In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998 • 2,777 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

1994 • 1,932 citations

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

2002 • 1,853 citations

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

1997 • 1,652 citations

The origin and function of tumor-associated macrophages

1992 • 1,081 citations

Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

1998 • 914 citations

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1984 • 714 citations

Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

2001 • 603 citations

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

2000 • 576 citations

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

1998 • 576 citations

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

2001 • 533 citations

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

2001 • 521 citations

The role of complement in inflammation and phagocytosis

1991 • 495 citations

European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

2000 • 485 citations

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

2001 • 425 citations

C5A Anaphylatoxin and Its Seven Transmembrane-Segment Receptor

1994 • 418 citations

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

2000 • 388 citations

Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines.

1995 • 318 citations

Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms

2000 • 251 citations

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

2001 • 220 citations

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species

2001 • 211 citations

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

1999 • 204 citations

Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.

2000 • 158 citations

Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy

1993 • 144 citations

CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells

2001 • 139 citations

Signaling antibodies in cancer therapy

1999 • 127 citations

Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy

1993 • 120 citations

Tumor B Cells From Non-Hodgkin's Lymphoma Are Resistant to CD95 (Fas/Apo-1)–Mediated Apoptosis

1998 • 118 citations

Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo

2002 • 80 citations

The Revised European‐American Classification of Lymphoid Neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas

1997 • 77 citations

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1984 • 62 citations

Malignant B lymphocytes from non‐Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: An important role of co‐stimulatory molecules CD80 (B7‐1) and CD86 (B7‐2) in stimulation by tumor cells

1995 • 46 citations

High-dose rituximab therapy in chronic lymphocytic leukemia.

2000 • 46 citations

Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma

2000 • 37 citations

The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells

1999 • 31 citations